Molecular Imaging As A Critical Tool In Discovery Of The Basis Of Tumour Heterogeneity And Developing Novel Therapies To Overcome Therapeutic Resistance
Funder
National Health and Medical Research Council
Funding Amount
$467,961.00
Summary
Determining treatment options for cancer currently relies on the size and extent of tumour deposits on imaging, combined with a biopsy. However, this approach fails to recognise the ability of tumours to evolve components that are, or become, resistant to treatment. My laboratory uses advanced molecular imaging, targeted biopsies, animal models and genetic analysis to detect and understand the basis of such resistance and thereby develop new, targeted treatments to improve patient outcomes.
HEREDITARY ENDOCRINE CANCER: A MODEL BASED ON PHAEOCHROMOCYTOMA- PARAGANGLIOMA SYNDROMES
Funder
National Health and Medical Research Council
Funding Amount
$875,894.00
Summary
Phaeochromocytomas and paragangliomas are tumours remarkable for their very high heritability. They have a high burden of disease themselves, and their associated hereditary syndromes include risks for other malignancies. Our study will rationalize the pathological approach to diagnosing these hereditary syndromes, find new therapeutic targets for metastatic disease, and provide a template for other cancers with high heritable component.
The Role Of The Cytokine Receptor Gp130 In Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$437,545.00
Summary
Prostate cancer is a leading cause of cancer deaths in men in the Western world. Neuroendocrine cells may play an important role in the development of these cancers, but their biology is essentially uncharacterized. Activation of the cell-bound protein gp130 results in neuroendocrine differentiation, growth and chemotherapeutic drug resistance of prostate cancer cells. We will use gp130-dependent differentiation to understand how neuroendocrine cells influence normal and cancerous prostate cells ....Prostate cancer is a leading cause of cancer deaths in men in the Western world. Neuroendocrine cells may play an important role in the development of these cancers, but their biology is essentially uncharacterized. Activation of the cell-bound protein gp130 results in neuroendocrine differentiation, growth and chemotherapeutic drug resistance of prostate cancer cells. We will use gp130-dependent differentiation to understand how neuroendocrine cells influence normal and cancerous prostate cells, and to identify neuroendocrine-cell specific genes that may be of diagnostic or therapeutic benefit in prostate cancer. Gp130 can be activated by a group of hormones called the interleukin-6 type cytokines in the presence of certain cell-bound proteins (receptors). If these receptors are inappropriately expressed in the prostate, inappropriate activation of gp130 could occur resulting in prostate cancer cell growth or neuroendocrine differentiation. If we can determine that these receptors are expressed in prostate cancer, but not in non-cancerous prostate, this would have diagnostic or therapeutic benefit.Read moreRead less